Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

by Bacchiocchi Antonella, Cheng Elaine, Ariyan Stephan, Pavlick Anna C, Sznol Mario, Rubinstein Jill C, Kluger Harriet M, Narayan Deepak, Halaban Ruth
Published 2010-07-01

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

by Anthony Stephen P, Stephenson Joe, Senzer Neil N, Cunningham C Casey, Eager Robert M, O'Day Steven J, Frenette Gary, Pavlick Anna C, Jones Barry, Uprichard Margaret, Nemunaitis John
Published 2009-07-01

Serum microRNAs as biomarkers for recurrence in melanoma

by Friedman Erica B, Shang Shulian, de Miera Eleazar, Fog Jacob, Teilum Maria, Ma Michelle W, Berman Russell S, Shapiro Richard L, Pavlick Anna C, Hernando Eva, Baker Adam, Shao Yongzhao, Osman Iman
Published 2012-08-01

Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients

by Buckley Michael T, Shapiro Richard L, Berman Russell S, Kaminio Hideko, Yee Herman, Darvishian Farbod, Christos Paul J, Warycha Melanie A, Yu Jessie Z, Liebes Leonard F, Pavlick Anna C, Polsky David, Brooks Peter C, Osman Iman
Published 2008-11-01